UK Markets close in 47 mins

Merus N.V. (MRUS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
26.50+0.60 (+2.32%)
As of 04:00PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close25.90
Open25.44
Bid24.03 x 800
Ask26.00 x 1100
Day's range24.50 - 26.73
52-week range16.14 - 33.09
Volume142,394
Avg. volume251,787
Market cap1.131B
Beta (5Y monthly)0.95
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Globe Newswire

    Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

    - The primary endpoint of Clinical Benefit Rate at 24 weeks with the triplet combination was met - The triplet combination showed clinically meaningful activity after 3 lines of anti-HER2 therapies including T-DM1 - Validates the potential of zenocutuzumab in additional indications outside NRG1 fusions UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing in

  • Globe Newswire

    Merus Presents Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today released clinical data on MCLA-145 from the phase 1 trial in patients with solid tumors at the ESMO Immuno-Oncology Congress 2021 being held virtually. “We are encouraged by the progress we are making with MCLA-145,” said

  • Globe Newswire

    Merus Announces Poster Presentation on Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of the abstract highlighting interim data, as of a July 14, 2021 cutoff, from the phase 1/2 trial of bispecific antibody MCLA-145 in patients with solid tumors. The e-poster will be presented at